Literature DB >> 32851455

A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation.

Hiroo Katsuya1, Haruna Kizuka-Sano2, Masako Yokoo3, Keisuke Kidoguchi2, Kyosuke Yamaguchi2, Atsujiro Nishioka2, Hiroshi Ureshino2, Yasushi Kubota2, Toshihiko Ando2, Shinji Naito4, Koichi Ohshima5, Shinya Kimura2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32851455     DOI： 10.1007/s00277-020-04218-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  9 in total

1.  Aberrant expression of CD10 and BCL6 in mantle cell lymphoma.

Authors:  Marco Pizzi; Claudio Agostinelli; Simona Righi; Anna Gazzola; Claudia Mannu; Francesca Galuppini; Matteo Fassan; Andrea Visentin; Francesco Piazza; Gianpietro C Semenzato; Massimo Rugge; Elena Sabattini
Journal:  Histopathology       Date:  2017-08-08       Impact factor: 5.087

2.  Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis.

Authors:  Huy Tran; Catherine Cheung; Devinder Gill; Ujjwal Dua; Jamie Nourse; Richard Boyle; Maher K Gandhi
Journal:  Nat Clin Pract Oncol       Date:  2008-02-19

3.  Spontaneous Regression of Methotrexate-related Lymphoproliferative Disorder with T-cell Large Granular Lymphocytosis.

Authors:  Hiroshi Ureshino; Chiho Kadota; Kazuya Kurogi; Masaharu Miyahara; Shinya Kimura
Journal:  Intern Med       Date:  2015-09-01       Impact factor: 1.271

4.  Immunophenotypic variations in mantle cell lymphoma.

Authors:  Juehua Gao; LoAnn Peterson; Beverly Nelson; Charles Goolsby; Yi-Hua Chen
Journal:  Am J Clin Pathol       Date:  2009-11       Impact factor: 2.493

5.  BCL6, MUM1, and CD10 expression in mantle cell lymphoma.

Authors:  Gabriela Gualco; Lawrence M Weiss; William J Harrington; Carlos E Bacchi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-03

6.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Authors:  Michael L Wang; Kristie A Blum; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Liang Zhang; Linda Baher; Mei Cheng; Dana Lee; Darrin M Beaupre; Simon Rule
Journal:  Blood       Date:  2015-06-09       Impact factor: 22.113

7.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

8.  Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders.

Authors:  Michihide Tokuhira; Jun-Ichi Tamaru; Masahiro Kizaki
Journal:  J Clin Exp Hematop       Date:  2019

9.  CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases.

Authors:  Jie Xu; L Jeffrey Medeiros; Annapurna Saksena; Michael Wang; Jiehao Zhou; Jingyi Li; C Cameron Yin; Guilin Tang; Lifu Wang; Pei Lin; Shaoying Li
Journal:  Oncotarget       Date:  2017-12-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.